United Therapeutics Co. (NASDAQ:UTHR) Stock Holdings Lifted by Barclays PLC

Barclays PLC lifted its stake in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 27.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 74,736 shares of the biotechnology company's stock after acquiring an additional 16,142 shares during the quarter. Barclays PLC owned 0.17% of United Therapeutics worth $26,368,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. Cerity Partners LLC boosted its position in shares of United Therapeutics by 30.4% in the 4th quarter. Cerity Partners LLC now owns 11,588 shares of the biotechnology company's stock valued at $4,098,000 after purchasing an additional 2,702 shares during the period. Milestone Asset Management LLC boosted its holdings in shares of United Therapeutics by 56.5% in the fourth quarter. Milestone Asset Management LLC now owns 2,874 shares of the biotechnology company's stock worth $1,014,000 after buying an additional 1,037 shares during the period. Korea Investment CORP boosted its holdings in shares of United Therapeutics by 6.2% in the fourth quarter. Korea Investment CORP now owns 39,289 shares of the biotechnology company's stock worth $13,863,000 after buying an additional 2,300 shares during the period. Janney Montgomery Scott LLC increased its position in shares of United Therapeutics by 9.1% in the fourth quarter. Janney Montgomery Scott LLC now owns 9,427 shares of the biotechnology company's stock worth $3,326,000 after acquiring an additional 789 shares in the last quarter. Finally, JPMorgan Chase & Co. raised its holdings in shares of United Therapeutics by 35.4% during the third quarter. JPMorgan Chase & Co. now owns 192,546 shares of the biotechnology company's stock valued at $68,999,000 after acquiring an additional 50,291 shares during the period. 94.08% of the stock is currently owned by institutional investors and hedge funds.

United Therapeutics Stock Down 0.2 %

NASDAQ UTHR opened at $284.73 on Friday. The company has a 50 day moving average price of $316.61 and a two-hundred day moving average price of $348.66. United Therapeutics Co. has a 12-month low of $233.28 and a 12-month high of $417.82. The stock has a market capitalization of $12.79 billion, a PE ratio of 12.50, a price-to-earnings-growth ratio of 0.97 and a beta of 0.63.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last released its quarterly earnings data on Wednesday, February 26th. The biotechnology company reported $6.19 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.10 by $0.09. The business had revenue of $735.90 million during the quarter, compared to analyst estimates of $734.74 million. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. During the same quarter in the previous year, the business earned $4.36 EPS. As a group, equities analysts anticipate that United Therapeutics Co. will post 24.48 EPS for the current year.

Insider Transactions at United Therapeutics

In related news, Director Tommy G. Thompson sold 2,500 shares of the business's stock in a transaction that occurred on Monday, March 24th. The stock was sold at an average price of $318.80, for a total value of $797,000.00. Following the completion of the sale, the director now directly owns 8,480 shares in the company, valued at approximately $2,703,424. The trade was a 22.77 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, COO Michael Benkowitz sold 10,000 shares of the stock in a transaction that occurred on Monday, January 27th. The shares were sold at an average price of $370.71, for a total value of $3,707,100.00. Following the transaction, the chief operating officer now owns 2,577 shares in the company, valued at approximately $955,319.67. This trade represents a 79.51 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 91,500 shares of company stock worth $30,971,540. 11.90% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on the stock. UBS Group raised their price objective on shares of United Therapeutics from $415.00 to $475.00 and gave the stock a "buy" rating in a research note on Wednesday, January 8th. StockNews.com raised United Therapeutics from a "buy" rating to a "strong-buy" rating in a research report on Thursday. Finally, HC Wainwright reissued a "buy" rating and set a $425.00 price target on shares of United Therapeutics in a research report on Thursday, February 27th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $388.25.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Co. (NASDAQ:UTHR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.